California Supreme Court
Feb. 15, 2012
The state Supreme Court on Wednesday breathed new life into antitrust claims against pharmaceutical companies over so-called "pay for delay" settlements.
By Laura Ernde
Daily Journal Staff Writer
The state Supreme Court Wednesday breathed new life into antitrust claims against pharmaceutical companies over so-called "pay for delay" settlements.
The deals allow drug manufacturers to settle patent litigation by agreeing to delay the launch of generic drugs. The Federal Trade Commission has criticized the practice as anti-competitive and estimated it costs consumers $3.5 billion a year.
Although federal and state...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In